Molecular Signatures of Lung Cancer — Toward Personalized Therapy

Abstract

Lung cancer is the deadliest cancer in the world. Relapses are frequent after primary and adjuvant therapy and often evolve into lethal metastatic disease. Currently, lung-cancer staging rests on histopathological and clinical criteria that have only limited power to predict relapse and survival. A major effort to improve the control of lung cancer entails the use of molecular profiling to characterize tumors and provide accurate predictions of the outcome after standard or novel treatments.Such molecular studies of lung tumors began with single or relatively small groups of potential prognostic markers and have progressed to microarray analyses of thousands of . . .